SK Bioscience targets 2029 PCV21 launch: KRW 52,000 target for SK Bioscience stock
Published on 10/14/2026 at 01:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPCV21 development and operating results
- SK Bioscience is targeting PCV21 commercialization in 2029.
- Second-quarter revenue fell 3.80 percent to KRW 156.0 billion.
- SK Bioscience secured KRW 300.0 billion in long-term funding for PCV21.
- Phase 3 results are expected in 2027.
SK Bioscience (ISIN KR7302440003) is targeting commercialization of its PCV21 vaccine candidate in 2029, while Heungkuk Securities kept a KRW 52,000 target for SK Bioscience stock on October 6, 2026, according to Seoul Economic Daily. The report framed PCV21 as a longer-term growth driver while the established vaccine business remains under pressure.
PCV21 sets a longer-term test
The candidate is in global Phase 3 trials, with major results expected in 2027 and a commercial launch target of 2029. The timing makes clinical execution the central valuation issue because the product is intended to extend SK Bioscience beyond its current vaccine portfolio.
SK Bioscience also secured KRW 300.0 billion in long-term liquidity from the National Growth Fund, according to Seoul Economic Daily. The funding is intended for PCV21 research, commercialization preparation and manufacturing upgrades, giving the development program a defined financing source.
Quarterly losses remain material
In the second quarter of 2026, revenue was KRW 156.0 billion, down 3.80 percent from the prior-year quarter, while operating loss was KRW 15.7 billion, according to ATS View. Net loss was KRW 14.1 billion, but the operating loss was narrower than the KRW 44.5 billion loss reported for the first quarter of 2026.
The contrast is important for investors: the company is financing a late-stage growth project while its latest quarterly revenue declined and losses continued. IDT Biologika, the German contract development and manufacturing subsidiary, provided a counterweight as its second-quarter revenue rose 0.20 percent year over year and it returned to operating profit, Seoul Economic Daily reported.
Three dated company developments
On August 14, 2026, SK Bioscience announced an application for a global Phase 1b study of an RSV preventive antibody on its investor-relations page, SK Bioscience reported. On October 2, 2026, the company announced a new Skycellflu influenza-vaccine advertising campaign, also listed on its investor-relations page. On October 6, 2026, the PCV21 program and its 2027 Phase 3 milestone became the latest dated growth narrative in the coverage cited above.
What comes next for PCV21?
The next substantive milestones are the expected Phase 3 results in 2027 and the targeted commercialization in 2029. Projected PCV21 sales of KRW 120.0 billion to KRW 220.0 billion in 2030 and 2031 provide a quantified benchmark for the program, although those figures remain estimates reported by Seoul Economic Daily.
Last Korea Exchange quotation
The last quoted price was KRW 36,450 on the Korea Exchange on October 13, 2026 at 3:30 p.m. KST. The 52-week range was KRW 31,800 to KRW 61,300, placing the latest quotation KRW 25,850 below the high.
SK Bioscience key data
- Company: SK bioscience Co.,Ltd.
- ISIN: KR7302440003
- Ticker: 302440
- Primary exchange: KOSPI
- Last price on Korea Exchange (as of October 13, 2026, 3:30 p.m. KST): KRW 36,450
- Market capitalization: KRW 2.9 trillion (as of October 13, 2026)
- 52-week range: KRW 31,800-KRW 61,300 (as of October 13, 2026)
- Sector / Industry: Healthcare / Biotechnology
Market context: Market report KOSPI.
